Aytu Biopharma (AYTU) Cash from Operations (2010 - 2026)

Aytu Biopharma (AYTU) has reported Cash from Operations for 17 consecutive years, with -$4.2 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Cash from Operations rose 35.21% year-over-year to -$4.2 million in Q1 2026; TTM through Mar 2026 was $1.7 million, a 130.35% increase from a year earlier, with the FY2025 full-year figure at -$1.9 million, down 39.55% from the prior year.
• Cash from Operations was -$4.2 million for Q1 2026 at Aytu Biopharma, down from $3.7 million in the prior quarter.
• Over five years, Cash from Operations peaked at $9.4 million in Q2 2023 and troughed at -$9.1 million in Q3 2022.
• A 5-year average of -$1.5 million and a median of -$788000.0 in 2024 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations jumped 2251.85% in 2024 and plunged 2441.34% in 2025, its largest moves.
• Over 5 years, Cash from Operations stood at -$2.5 million in 2022, then jumped by 94.49% to -$135000.0 in 2023, then jumped by 2251.85% to $2.9 million in 2024, then climbed by 26.51% to $3.7 million in 2025, then sank by 213.8% to -$4.2 million in 2026.
• The last three Cash from Operations figures came in at -$4.2 million (Q1 2026), $3.7 million (Q4 2025), and -$618000.0 (Q3 2025), per Business Quant data.